Who Paid My Doc
A Randomized Phase II Trial of Salvage Radiotherapy With Standard VS Enhanced Androgen Deprivation Therapy With Enzalutamide in Patients With Postprostatectomy Psa Recurrences With Aggressive Disease Features
Research payments
$64,627,008
Through program year 2024, $64,627,008 in research payments was reported against A Randomized Phase II Trial of Salvage Radiotherapy With Standard VS Enhanced Androgen Deprivation Therapy With Enzalutamide in Patients With Postprostatectomy Psa Recurrences With Aggressive Disease Features, across 11 payments, paid by Pfizer Inc..
- Paid by
- Pfizer Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
6 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $7,405,113 | 1 |
| 2023 | Research | $14,104,969 | 2 |
| 2022 | Research | $25,479,941 | 4 |
| 2021 | Research | $5,073,584 | 2 |
| 2020 | Research | $5,911,407 | 1 |
| 2019 | Research | $6,651,994 | 1 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
1 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.